About xvivo perfusion - XVIPF
Xvivo Perfusion AB is a medical technology company operates in the field of organ transplantation technology. It involves in developing and marketing solutions and systems for assessing the usability of organs, and maintaining organs in good condition outside the body pending transplantation. Its products include XPS, XPS Disposable Kit, Steen Solution, Organ Chamber, Lung Cannula Set, Perfadex and Silicone Tubing Set. The company operates through the following segments: Thoracic, Abdominal and Services. The Thoracic segment engages in the sale of products for lung and heart transplantation. The Abdominal segment engages in the sale of products for liver and kidney transplantation. The Services segment engages in providing organ recovery-related services. The company was founded by Magnus Nilsson on December 17, 1998 and is headquartered in Gothenburg, Sweden.
XVIPF At a Glance
Xvivo Perfusion AB
Gemenskapens gata 9
Mölndal, Vastra Gotaland 431 53
| Phone | 46-31-788-21-50 | Revenue | 82.81M | |
| Industry | Medical Specialties | Net Income | 2.57M | |
| Sector | Health Technology | 2025 Sales Growth | 6.459% | |
| Fiscal Year-end | 12 / 2026 | Employees | 210 | |
| View SEC Filings |
XVIPF Valuation
| P/E Current | 123.386 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 248.359 |
| Price to Sales Ratio | 7.713 |
| Price to Book Ratio | 2.781 |
| Price to Cash Flow Ratio | 61.98 |
| Enterprise Value to EBITDA | 37.289 |
| Enterprise Value to Sales | 7.494 |
| Total Debt to Enterprise Value | 0.022 |
XVIPF Efficiency
| Revenue/Employee | 394,335.852 |
| Income Per Employee | 12,217.558 |
| Receivables Turnover | 6.425 |
| Total Asset Turnover | 0.349 |
XVIPF Liquidity
| Current Ratio | 5.765 |
| Quick Ratio | 3.684 |
| Cash Ratio | 2.447 |
XVIPF Profitability
| Gross Margin | 65.688 |
| Operating Margin | 11.453 |
| Pretax Margin | 4.748 |
| Net Margin | 3.098 |
| Return on Assets | 1.08 |
| Return on Equity | 1.209 |
| Return on Total Capital | 1.057 |
| Return on Invested Capital | 1.169 |
XVIPF Capital Structure
| Total Debt to Total Equity | 5.901 |
| Total Debt to Total Capital | 5.572 |
| Total Debt to Total Assets | 5.253 |
| Long-Term Debt to Equity | 5.354 |
| Long-Term Debt to Total Capital | 5.056 |